Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Portfolio Pulse from
Aptose Biosciences has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop its drug tuspetinib for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) as part of the MyeloMATCH precision medicine trials. Tuspetinib was chosen for its potential to target a broad spectrum of AML and MDS populations.
December 03, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptose Biosciences has entered a CRADA with the NCI to develop tuspetinib for AML and MDS, enhancing its potential market reach and credibility.
The partnership with NCI, a prestigious institution, enhances the credibility and potential market reach of Aptose's drug tuspetinib. This could lead to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90